O
KNSA icon

OrbiMed’s Kiniksa Pharmaceuticals KNSA Stock Holding History

OrbiMed’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9M Buy
420,600
+240,001
+133% +$12.4M 0.5% 52
2026
Q1 		$8.7M Sell
180,599
-6,600
-4% -$292K 0.17% 81
2025
Q4 		$7.72M Buy
+187,199
New +$7.51M 0.16% 86

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

OrbiMed's KNSA Position: Q2 2026 in Review

OrbiMed increased its Kiniksa Pharmaceuticals (KNSA) stake by 133% in Q2 2026, buying an estimated $12.4M and bringing the position to 420,600 shares worth $26.9M. The position accounts for 0.5% of the portfolio, ranked #52.

OrbiMed first reported a position in KNSA in Q4 2025 and has held it in 3 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • OrbiMed held 420,600 shares of Kiniksa Pharmaceuticals worth $26.9M as of Q2 2026.
  • OrbiMed bought 240,001 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $12.4M.
  • Kiniksa Pharmaceuticals made up 0.5% of OrbiMed's portfolio in Q2 2026, its #52 holding.
  • OrbiMed first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.